Barclays PLC Has $174,000 Position in Sanara MedTech Inc. (NASDAQ:SMTI)

Barclays PLC raised its position in shares of Sanara MedTech Inc. (NASDAQ:SMTIFree Report) by 323.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,731 shares of the company’s stock after purchasing an additional 4,376 shares during the quarter. Barclays PLC owned 0.07% of Sanara MedTech worth $174,000 at the end of the most recent quarter.

Separately, Geode Capital Management LLC raised its stake in Sanara MedTech by 4.4% during the 3rd quarter. Geode Capital Management LLC now owns 88,271 shares of the company’s stock valued at $2,670,000 after purchasing an additional 3,755 shares during the period. Institutional investors own 8.10% of the company’s stock.

Sanara MedTech Trading Up 10.9 %

NASDAQ SMTI opened at $37.72 on Thursday. Sanara MedTech Inc. has a 1-year low of $26.00 and a 1-year high of $40.75. The company has a current ratio of 2.23, a quick ratio of 2.02 and a debt-to-equity ratio of 0.76. The company has a market capitalization of $329.67 million, a PE ratio of -38.10 and a beta of 1.55. The firm’s fifty day simple moving average is $34.65 and its 200-day simple moving average is $32.80.

Sanara MedTech (NASDAQ:SMTIGet Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.28. The firm had revenue of $21.67 million for the quarter. Sanara MedTech had a negative net margin of 10.71% and a negative return on equity of 19.86%. During the same period in the previous year, the company earned ($0.13) earnings per share. As a group, sell-side analysts anticipate that Sanara MedTech Inc. will post -1.33 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on SMTI. Cantor Fitzgerald reissued an “overweight” rating and set a $44.00 target price on shares of Sanara MedTech in a research note on Wednesday. HC Wainwright started coverage on shares of Sanara MedTech in a research note on Monday, December 23rd. They issued a “buy” rating and a $50.00 price target on the stock.

Check Out Our Latest Stock Analysis on SMTI

Sanara MedTech Company Profile

(Free Report)

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.

Recommended Stories

Institutional Ownership by Quarter for Sanara MedTech (NASDAQ:SMTI)

Receive News & Ratings for Sanara MedTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanara MedTech and related companies with MarketBeat.com's FREE daily email newsletter.